GNPS CF1 4y longitudinal
Ontology highlight
ABSTRACT:
INSTRUMENT(S): maXis
ORGANISM(S): Homo Sapiens (ncbitaxon:9606)
SUBMITTER: Dorrestein/Rohwer
PROVIDER: MSV000079444 | GNPS | Tue Jan 05 14:47:00 GMT 2016
REPOSITORIES: GNPS
Similar Datasets
Project description:Epigenetic dysregulation is implicated in the pathogenesis of lupus. We performed a longitudinal analysis to assess changes in DNA methylation in neutrophils collected from 54 lupus patients over 4 years of follow up and across disease activity levels using 229 patient samples.
2020-12-08 | GSE161476 | GEO
Project description:Longitudinal sputum samples collected from multiple patients in 2011-2012
2016-01-05 | MSV000079443 | GNPS
Project description:To better understand the molecular determinants of lung disease variability among patients with cystic fibrosis (CF), we carried out an epigenome-wide association study (EWAS) in sputum samples from patients with CF. Sputum samples were collected from 50 patients with CF at four time points (visit 1, 2, 3 and 4) over an 18-month follow-up period. We profiled 64 sputum samples collected at visit 1 and 2, using human methylation BeadChips (EPIC). Selected CpG sites were reassessed in independent sputum samples collected at visit 3 and 4, by pyrosequencing. Overall, we provide the first longitudinal assessment of genome-wide DNA methylation in a cohort of patients with CF and identify CpG sites that predict clinical traits of key importance for lung disease. Specifically, we identified (i) differentially methylated CpG sites that correlate with lung function (FEV1pp), (ii) a DNA methylation signature that predicts patients with a pulmonary exacerbation and (iii) CpG sites that split patients with declining lung function from those whose lung function either improved or remained stable.
2026-01-21 | GSE289379 | GEO
Project description:Multiple myeloma (MM) is a hematological malignancy characterized by an expansion of malignant plasma cells in the bone marrow. For newly diagnosed MM (NDMM), standard three-drug treatment regimens—such as the combination of bortezomib, lenalidomide, and dexamethasone (VRd)—and the more recent inclusion of a fourth drug, anti-CD38 antibody immunotherapy, have significantly improved patient outcomes by targeting multiple mechanisms of tumorigenesis. This treatment approach typically involves several cycles of VRd induction therapy, followed by high dose melphalan (HDM) and autologous stem cell transplant (ASCT), and maintenance therapy. Treatment responses vary widely, with some patients requiring longer and more intense therapy and others exhibiting more rapid responses and longer relapse-free remission.This cycle of remission, maintenance, and eventual relapse persists despite advancements in treatment modalities, including immunotherapy, leaving MM incurable. This study characterizes the tumor state and immune microenvironment in MM patients across variable graded patient responses. Using a multimodal, longitudinal approach, we investigate immune and microenvironmental cellular changes during treatment in NDMM patients and in a second cohort of RRMM patients. For the NDMM cohort, longitudinal blood and bone marrow aspirate samples were collected at diagnosis, throughout induction therapy, following autologous stem cell transplant (ASCT), and at post-transplant intervals of 60 days, 90 days, and 1 and 2 years. Multi-omic profiling of these samples magnifies the individual heterogeneity between tumor and therapeutic response. The longitudinal aspect of the study allowed us to focus on individual-level longitudinal responses instead of cross-patient effects, enabling detailed insights into tumor and microenvironment dynamics. Using Olink proteomic analysis of plasma and bone marrow interstitial fluid (BMIF), and single-cell analyses (3’ CITE-seq, scRNA-seq, flow cytometry) of peripheral blood mononuclear cells (PBMC) and bone marrow mononuclear cells (BMMC) we longitudinally characterized tumor, the immune microenvironment, and therapeutic responses. This revealed distinct immune states and pathways associated with therapeutic response, and tumor survival, highlighting potential targets and therapeutic strategies to improve patient outcomes.
2026-07-15 | GSE309595 | GEO
Project description:Multiple myeloma (MM) is a hematological malignancy characterized by an expansion of malignant plasma cells in the bone marrow. For newly diagnosed MM (NDMM), standard three-drug treatment regimens—such as the combination of bortezomib, lenalidomide, and dexamethasone (VRd)—and the more recent inclusion of a fourth drug, anti-CD38 antibody immunotherapy, have significantly improved patient outcomes by targeting multiple mechanisms of tumorigenesis. This treatment approach typically involves several cycles of VRd induction therapy, followed by high dose melphalan (HDM) and autologous stem cell transplant (ASCT), and maintenance therapy. Treatment responses vary widely, with some patients requiring longer and more intense therapy and others exhibiting more rapid responses and longer relapse-free remission.This cycle of remission, maintenance, and eventual relapse persists despite advancements in treatment modalities, including immunotherapy, leaving MM incurable. This study characterizes the tumor state and immune microenvironment in MM patients across variable graded patient responses. Using a multimodal, longitudinal approach, we investigate immune and microenvironmental cellular changes during treatment in NDMM patients and in a second cohort of RRMM patients. For the NDMM cohort, longitudinal blood and bone marrow aspirate samples were collected at diagnosis, throughout induction therapy, following autologous stem cell transplant (ASCT), and at post-transplant intervals of 60 days, 90 days, and 1 and 2 years. Multi-omic profiling of these samples magnifies the individual heterogeneity between tumor and therapeutic response. The longitudinal aspect of the study allowed us to focus on individual-level longitudinal responses instead of cross-patient effects, enabling detailed insights into tumor and microenvironment dynamics. Using Olink proteomic analysis of plasma and bone marrow interstitial fluid (BMIF), and single-cell analyses (3’ CITE-seq, scRNA-seq, flow cytometry) of peripheral blood mononuclear cells (PBMC) and bone marrow mononuclear cells (BMMC) we longitudinally characterized tumor, the immune microenvironment, and therapeutic responses. This revealed distinct immune states and pathways associated with therapeutic response, and tumor survival, highlighting potential targets and therapeutic strategies to improve patient outcomes.
2026-07-15 | GSE309593 | GEO
Project description:Little is known about the lung microbiome dynamics and host-microbiome interactions in relation to chronic obstructive pulmonary disease (COPD) exacerbations and in patient subgroups based on smoking status and disease severity. Here we performed a 16S ribosomal RNA survey on sputum microbiome from 16 healthy and 43 COPD subjects. For COPD subjects, a longitudinal sampling was performed from stable state to exacerbations, at two and six weeks post-exacerbations and at six months from first stable visit. Host sputum transcriptome were characterized for a subset of COPD patient samples.
2021-03-21 | GSE112165 | GEO
Project description:This dataset consists of single-cell RNA sequencing (scRNA-seq) data derived from Peripheral Blood Mononuclear Cells (PBMCs) of two ischaemic stroke patients (P66 and P79). The study follows a longitudinal design to identify temporal changes in the systemic immune response, with samples collected at two timepoints: the acute in-patient stage (V1) and at 6-9 months follow-up (V3). Here, four samples (P66_V1, P66_V3, P79_V1, P79_V3) were multiplexed using the 10x Genomics CellPlex protocol and processed as a single pool. Approximately 33,000 cells were loaded onto a 10x Chromium Controller using the Chromium Next GEM Single Cell 5' Reagent Kit. This specific library represents the Gene Expression (GEX) portion of a multi-modal immune profiling experiment. The primary objective of this study was to assess the dynamics of the circulating immune compartment following ischaemic stroke.
2026-03-05 | E-MTAB-16654 | biostudies-arrayexpress
Project description:A longitudinal collection of sputum samples from a non-CF patient
2016-12-02 | MSV000080377 | GNPS
Project description:The aim of the longitudinal analysis was to examine the transcriptional blood profile of active TB patients at the time of recruitment (before drug treatment) and then subsequently at specific time points after drug treatment to determine whether the signature is extinguished with treatment and when. Whole blood collected in tempus tubes from patients with different spectra of TB disease and healthy controls. All patients were sampled prior to the initiation of any antimycobacterial therapy. Active Pulmonary TB: PTB - All patients confirmed by isolation of Mycobacterium Tuberculosis on culture of sputum or bronchoalvelolar lavage fluid. Healthy controls - these were volunteers without exposure to TB who were negative by both tuberculin skin test (<15mm if BCG vaccinated, <6mm if unvaccinated); who were also negative by Interferon-Gamma Release assay(IGRA); specifically Quantiferon Gold In-Tube Assay (Cellestis, Australia). Here the aim of the experiment is to assess the longitudinal effect of antimycobacterial treatment on the active TB signature, during and after treatment. Blood was taken from the active TB patients at baseline, pre-treatment, 2 months after treatment inititation, and 12 months after treatment initiation, which would be after treatment was completed. These samples were then amplified at the same time with samples from healthy controls and hybridised to the same chips to permit an assessment of whether the post treatment samples had similar transcriptional profiles to healthy controls or were distinct. In this dataset: PTB baseline, n = 7; PTB 2 months, n = 7; PTB 12 months, n = 7. BCG+ control baseline, n =12. Experimental variables: Patient group: Active PTB; Healthy controls (all BCG vaccinated). ethnicity - a wide range of ethnic groups is represented. The active PTB group incorporates a range of smear positive and smear negative disease and a spectrum of disease extent/severity. Timepoint: 0 months = baseline pre-treatment;2 months = 2 months after initiation of treatment; 12 months = 12 months after initiation of treatment.
2010-08-11 | E-GEOD-19435 | biostudies-arrayexpress
Project description:Genome-wide patterns of DNA methylation were quantified using the Illumina Infinium EPIC array (“EPIC array”) in DNA samples isolated from buccal swabs collected at ages 5, 10 and 18 and whole blood samples collected at age 18 from 118 Monozygotic twin pairs from the Environmental Risk (E-Risk) Longitudinal Twin Study. Comparison of DNA methylation profiles of 233 age 18 blood samples with data on EPIC and Illumina 450K methylation arrays.
2020-12-15 | GSE154566 | GEO